MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
230.02
+3.82
+1.69%
After Hours: 232.00 +1.98 +0.86% 17:01 06/26 EDT
OPEN
226.20
PREV CLOSE
226.20
HIGH
231.14
LOW
226.20
VOLUME
845.91K
TURNOVER
--
52 WEEK HIGH
243.32
52 WEEK LOW
105.00
MARKET CAP
14.45B
P/E (TTM)
2163.88
1D
5D
1M
3M
1Y
5Y
1D
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Seeking Alpha · 9h ago
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value?
Simply Wall St · 1d ago
ANALYSIS-US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Reuters · 1d ago
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
The Motley Fool · 3d ago
Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative?
Simply Wall St · 3d ago
Weekly Report: what happened at JAZZ last week (0615-0619)?
Weekly Report · 4d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Simply Wall St · 06/18 15:26
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.